Next-generation immunotherapies for cancer patients – Kineta Inc.

Kineta enters definitive agreement to be acquired by TuHURA Biosciences.
See press release for important details.

KINETA24_hp_slider_grandpa_FIN

Developing
next-generation immunotherapies

KINETA24_hp_slider_momandson_FIN

Addressing
mechanisms of
cancer immune resistance

KINETA_web_hp_slider_antibody

KVA 12123
VISTA blocking
cancer therapy